Efficacy of Purslane in Treatment of Oral Lichen Planus

• Status: Completed
• Trial end date: 2008-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Oral lichen planus (OLP) is a chronic inflammatory disease whose prevalence in the general population is 0.5 -2.2%.Oral lesions in OLP are chronic, rarely undergo spontaneous remission. Patients with OLP had significantly increased risk of oral squamous cell carcinoma, irrespective of the clinical type of OLP and therapy. there is currently no cure for OLP. Previous study demonstrated a decreased antioxidant defence and increased oxidative damage to lipids.DNA and proteins in lichen planus. This oxidative modifications point to pathophysiological alterations mainly within the basal cell layers of epidermis and at the dermoepidermal junction. Purslane is an excellent source of vitamin A,C and E and essential amino acids, has been described as a power food of the future because of its high nutritive and antioxidant properties. The purpose of the study was to determined the efficacy of Purslane in the treatment of oral lichen planus.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Qazvin University Of Medical Sciences
• Treatments: Antioxidants

Criteria

Inclusion Criteria:

• Biopsy confirmed symptomatic oral lichen planus: WHO histological criteria in combination with clinical appearance will be used for diagnosis

• Patients who had symptoms such as burning sensation, pain

• Patients not on any immunosuppressive or immunomodulatory treatment. In case they were,then such treatment should be stopped and a washout period of 1 month was given.

• Patients of both sexes between 30 to 70 year's old

• Patients who gave written informed consent

• Patients who were willing for evaluation in second week after therapy and every 1 month up to 6 months

Exclusion Criteria:

• The presence of histological signs of dysplasia

• Patients suffering from any localized or systemic disease

• Renal disease patients

• Pregnant patients

• Patients who can not continue the study for private or social reasons

• Patients who used lichenoid reaction including drugs